IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?

Core Viewpoint - IDEXX Laboratories, Inc. (IDXX) is expected to release its fourth-quarter 2024 results on February 3, with estimates indicating revenue growth and earnings per share (EPS) increase compared to the previous year [1][3]. Revenue Estimates - The Zacks Consensus Estimate for revenues is $936.8 million, reflecting a 3.9% increase from the year-ago figure [3]. - The Zacks Consensus Estimate for EPS is $2.40, indicating a 3.4% increase from the year-ago figure [3]. Performance Factors - Companion Animal Group (CAG) Diagnostics is anticipated to have recurring revenues supported by improved global net prices and international organic growth, driven by strong execution of strategies [5]. - U.S. CAG Diagnostics revenues likely benefited from new business gains, high customer retention, and increased diagnostic utilization per clinical visit [6]. - IDEXX VetLab consumables are expected to show strong organic growth, particularly in the U.S. and international markets [7]. - The point-of-care business has seen positive initial customer responses to new products, which are expected to favor segment revenues [8]. Segment Performance - Global rapid assays revenues are likely to have increased due to higher net price realization and strong performance in the U.S. and international regions [10]. - The reference lab, veterinary software, and diagnostic imaging revenues are expected to benefit from the acquisition of Greenline software, with organic growth driven by recurring revenues [11]. - The Water segment is projected to achieve strong organic revenues due to increased volumes in the U.S. and Europe, although a decline of 9% year-over-year is expected [12]. - The Livestock, Poultry, and Dairy (LPD) division is likely to experience a revenue decline due to reduced swine testing in China, despite a projected 7.2% year-over-year increase in revenues [13]. Earnings ESP and Zacks Rank - IDEXX Laboratories has an Earnings ESP of 0.00%, indicating no expected surprise in earnings [14]. - The company currently holds a Zacks Rank of 4 (Sell), suggesting a lower likelihood of beating estimates [14].